Biotechvana

Patents and trademarks

2020

Title: GPRO Suite. Authors: AHMED HAFEZ, BEATRIZ SORIANO, CARLOS LLORENS Request NO: V-959-20, ENTRY NUMBER: 09/2023/9 Priority date: 23-11-2020 Entity: BIOTECH VANA S.LCountry: SPAIN Companies exploiting IT: BIOTECH VANA S.L (software).

2011

Title: GPRO 1.0 Authors: RICARDO FUTAMI, ALFONSO MUNOZ-POMER, JOSE MARIA VIU, LAURA DOMÍNGUEZ-ESCRIBÁ, LAURA COVELLI, GUILLERMO PABLO BERNET, ANDRÉS MOYA, CARLOS LLORENS Request NO: V-13-11, ENTRY NUMBER: 09/2013/1283 Priority date: 2013 Entity: BIOTECH VANA S.LCountry: SPAIN Companies exploiting IT: BIOTECH VANA S.L (software).

2010

Title: CHECKALIGN 2.0 Authors: ALFONSO MUÑOZ-POMER, RICARDO FUTAMI, ANDRES MOYA, CARLOS LLORENS Request NO: V-2137-10, ENTRY NUMBER: 09/2013/1281 Priority date: 2013 Entity: BIOTECH VANA S.L Country: SPAIN Companies exploiting IT: BIOTECH VANA S.L (SOFTWARE).

Title: BIOTECHVANA TIME (TOOL FOR IN-PLACE MOLECULAR EDITING) Authors: ALFONSO MUÑOZ-POMER, RICARDO FUTAMI, LAURA COVELLI, GUILLERMO BERNET, GONZALO FUSTER, ANDRES MOYA, CARLOS LLORENS Request NO: V-1683-10, ENTRY NUMBER: 09/2013/1277 Priority date: 2013 Entity: BIOTECH VANA S.L Country: SPAIN Companies exploiting IT: BIOTECH VANA S.L (software).

Title: THE GYPSY DATABASE (GYDB) OF MOBILE GENETIC ELEMENTS RELEASE 2.0 Authors: CARLOS LLORENS, RICARDO FUTAMI, LAURA COVELLI, LAURA DOMINGUEZ, ALFONSO MUÑOZ-POMER, JOSE MARIA VIU, GONZALO FUSTER, ANDRÉS MOYA Request NO: V-1307-10, ENTRY NUMBER: 09/2013/1263 Priority Country: 2013 Priority date: Awaiting Entity: BIOTECH VANA S.L Country: SPAIN Companies exploiting IT: FREELY ACCESIBLE WORLWIDE.

2007

Title: CHECKALIGN Authors: CARLOS LLORENS AND RICARDO FUTAMI Request NO: RTV-129-07 ENTRY NUMBER: 09/2007/2241 Priority Country: SPAIN Priority date: 18-01-2008 Entity: BIOTECH VANA S.L Country: SPAIN Companies exploiting IT: FREELY ACCESIBLE WORLWIDEComments: We are only registering authors of the informatic software algorithms (the tool). Computed algorithms (functions and methods) are based on prior research properly cited in the work.

Title: BIOTECHVANA BIOINFORMATICS Authors: CARLOS LLORENS AND RICARDO FUTAMI Request NO: ISSN 1234-5678 Priority Country: WORLDWIDE Priority date: 24-07-2007 Entity: BIOTECH VANA S.LCountry: WORLDWIDE Companies exploiting IT: FREELY ACCESIBLE WORLWIDE.

Title: BIOTECHVANA Authors: CARLOS LLORENS AND RICARDO FUTAMI Priority Country: SPAIN Request NO: 2.791.187 (X) Priority date: 24-07-2007 Entity: BIOTECH VANA S.LCountry: SPAIN Companies exploiting IT: FREELY ACCESIBLE WORLWIDE.

2006

Title: GYPSY DATABASE (GYDB) OF MOBILE GENETIC ELEMENTS VERSION 1 Authors: CARLOS LLORENS AND RICARDO FUTAMI Request NO: RTV-1392-06 ENTRY NUMBER: 09/2007/1000 Priority Country: WORLDWIDE Priority date: 11-01-2008 Entity: BIOTECH VANA S.L Country: SPAINCompanies exploiting IT: FREELY ACCESIBLE WORLWIDE.

Title: PHYLO 1.0 Authors: CARLOS LLORENS AND RICARDO FUTAMI Request NO: RTV-1393-06 ENTRY NUMBER: 09/2007/1001 Priority Country: SPAIN Priority date: 11-01-2008 Entity: BIOTECH VANA S.L Country: SPAIN Companies exploiting IT: FREELY ACCESIBLE WORLWIDE.

Title: GYPSY DATABASE (GYDB) OF MOBILE GENETIC ELEMENTS (Trademark) Authors: CARLOS LLORENS AND RICARDO FUTAMI Priority Country: WORLDWIDE Request NO: 891 161 Priority date: 04-05-2006 Entity: BIOTECH VANA S.L Country: EUROPE, EEUU, CANADA, JAPAN AND OTHERSCompanies exploiting IT: FREELY ACCESIBLE WORLWIDE.

Biotechvana

Valencia Lab

Parc Cientific Universitat de Valencia
Carrer del Catedràtic Agustín Escardino, 9. 46980 Paterna (Valencia) Spain

Madrid Lab

Parque Científico de Madrid
Campus de Cantoblanco
Calle Faraday 7, 28049 Madrid Spain

Phone: +34 960 06 74 93
Email: biotechvana(at)biotechvana.com

Supported by

Hipra Scientific S.L.U, Polypeptide Therapeutic Solutions S.L., Biotechvana S.L. and Nostrum Biodiscovery constitute the consortium of enterprises participating in the project "Research of a new vaccine for a human respiratory disease", granted by the CDTI (Center for Industrial Technological Development), and supported by the Ministry of Science and Innovation and financed by the European Union – NextGenerationEU. The main objective of this project is to design a safe immunogenic and effective vaccine against the respiratory syncytial virus.